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A systematic review and meta-analysis of the 
prevalence of common mental disorders in 
people with non-communicable diseases in 
Bangladesh, India, and Pakistan
Background The prevalence of mental and physical comorbid-
ities is unknown in South Asia, as estimates of mental ill health 
in patients with non-communicable diseases (NCDs) have pre-
dominantly come from studies based in the United States, Europe 
and Australasia. This systematic review and meta-analysis sum-
marises evidence and provides pooled estimates of the prevalence 
of common mental disorders in adults with non-communicable 
diseases in South Asia.
Methods We included prevalence studies of depression and anx-
iety in adults with diabetes, cancer, cardiovascular disease, and 
chronic respiratory conditions in Bangladesh, India, and Paki-
stan, published from 1990 onwards in international and coun-
try-specific databases.
Results Out of 96 included studies, 83 provided data for random 
effects meta-analyses. The pooled prevalence of depression was 
44% (95% confidence interval (CI) = 26 to 62) for patients with 
COPD, 40% (95% CI = 34 to 45) for diabetes, 39% (95% CI = 23 
to 56) for stroke, 38% (95% CI = 32 to 45) for hypertension, and 
37% (95% CI = 30 to 45) for cancer. The pooled prevalence of 
anxiety based on 28 studies was 29% (95% CI = 22 to 36). Many 
quality issues were identified in a critical appraisal of included 
studies, mostly relating to the sampling frame and selection pro-
cess, the description of the methods and basic data, and the de-
scription of non-responders.
Conclusions Depression and anxiety are prevalent and underdi-
agnosed in people with physical comorbidities in Bangladesh, 
India, and Pakistan.
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The online version of this article contains supplementary material.
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Common mental disorders and non-communicable 
diseases
The WHO estimated that 4.4% of the global population was living 
with depression and 3.6% was suffering from an anxiety disorder in 
2015 [1]. In low- and middle-income countries, the burden of dis-
ease caused by common mental disorders (CMDs), such as depres-
sion and anxiety, and non-communicable diseases (NCDs), such as 
diabetes and COPD, is high [1]. While the burden of some NCDs 
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such as cancer and diabetes is on the rise, trends in the global burden of mental illness vary between 
world regions and types of disorders. In analyses with data from 1990, 2007, and 2017, depressive and 
anxiety disorders consistently occupied the top twenty of leading causes of the global burden of dis-
ease for men and women [2]. The prevalence of CMDs is higher among people with a physical NCD, 
than among those without. In the WHO World Health Surveys, between 9 and 23% of participants 
with one or more chronic physical conditions had comorbid depression [3]. In low- and middle-in-
come countries, resources and access to health care for CMDs remain limited [4]. As a result, patients 
with comorbid physical and mental ill health are less likely to be identified, diagnosed, and treated [5].
Integrated mental health as a global priority
There is now global consensus that the high burden of mental ill health combined with lack of access to 
high quality mental health services in low- and middle-income countries should be a priority for sustain-
able development [6]. NCDs are included in the Sustainable Development goals, and the Lancet Com-
mission on Global Mental Health and Sustainable Development has put the integration of mental health 
services at the very top of the global policy agenda [7].
Building on the momentum created to address these challenges, the IMPACT project (Improving Men-
tal and Physical Health Together, https://www.york.ac.uk/healthsciences/research/mental-health/projects/
impact/) aims to improve the mental health of people with physical conditions, and the physical health 
of people with mental ill health, in South Asia. By undertaking a rapid evidence review of the burden of 
physical and mental health comorbidities in Bangladesh, India, and Pakistan, we will inform the devel-
opment, implementation, and evaluation of interventions within the IMPACT project.
Focus on Bangladesh, India, and Pakistan
In 2017, people living in Bangladesh, India, and Pakistan comprised more than 22% of the world’s pop-
ulation [8]. A growing number of people in these countries are living with NCDs. Data from India show 
that major risk factors, such as high systolic blood pressure, high fasting plasma glucose, high total cho-
lesterol, and high body-mass index, have become more prevalent [9].
Of the total number of years of life lost globally due to premature mortality and disability because of chron-
ic respiratory conditions, 32% of Disability Adjusted Life Years (DALYs) were lost in India [10]. Ischemic 
heart disease is the leading cause of lost DALYs in Pakistan, India, and Bangladesh, stroke is in the top 
10 leading causes in all three countries, and chronic obstructive pulmonary disease (COPD) is in the top 
five in India and Bangladesh [11]. More than 18% of men and 15% of women in India over the age of 
60 were living with diabetes in 2016 [12]. Many more live with poorly controlled and undiagnosed dia-
betes, with one study estimating that around 32 million people live with undiagnosed diabetes in India 
[13]. This increases the risk of developing diabetic complications, as well as the risk of developing other 
NCDs which often co-exist with diabetes, such as coronary artery disease [14].
In addition to the large growing burden of NCDs, the WHO estimates that 27% of all people with de-
pressive disorders and 23% of people with anxiety disorders live in South-East Asia, making this an im-
portant region to focus efforts on the integration of mental health services into systems for treatment of 
NCDs [1]. The prevalence of mental and physical comorbidities however is unknown in these countries, 
as estimates of mental ill health in patients with NCDs have predominantly come from studies based in 
the United States, Europe and Australasia.
Aim and objectives
The aim of this systematic review and meta-analysis is to summarise the evidence and provide pooled es-
timates of the prevalence of CMDs in adults with NCDs in Bangladesh, India, and Pakistan, to inform the 
development, implementation, and evaluation of interventions within the IMPACT project. To achieve 
this aim, we have three objectives. First, we will identify evidence and meta-analyse available data from 
studies exploring the prevalence of CMDs in adults with NCDs in Bangladesh, India, and Pakistan. Sec-
ond, we plan to summarise evidence on determinants of CMDs in adults with NCDs, and third, we aim 
to explore variation in the prevalence of CMDs in adults with NCDs in Bangladesh, India, and Pakistan. 
We will focus this review on prevalence rates of depression and anxiety, representing the two most prev-
alent CMDs worldwide. We will consider NCDs in the following broad categories of illness: type II dia-
betes, cancer, cardiovascular disease, and chronic respiratory disease.
Common mental disorders in Bangladesh, India and Pakistan
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METHODS
This systematic review and meta-analysis follows the Centre for Reviews and Dissemination Handbook 
and the guidance for reporting of Meta-analyses Of Observational Studies in Epidemiology (MOOSE) 
[15,16]. The PROSPERO database contains a brief version of the protocol (http://www.crd.york.ac.uk/
PROSPERO/display_record.php?ID=CRD42018106502) and the full protocol is available from the study 
website (https://www.york.ac.uk/healthsciences/research/mental-health/projects/impact/impact-outputs/).
Data sources and search strategy
A senior information specialist (JuW) conducted test searches to identify appropriate global health and 
Asian country-specific databases and web resources for relevant evidence. We searched the following da-
tabases and web resources during July to October 2018: BRAC Research & Publication website, Cochrane 
Database of Systematic Reviews (Wiley), Database of Abstracts of Reviews of Effect (Wiley), Global Health 
(Ovid), Global Index Medicus (World Health Organization) Libraries, Health Technology Assessment Da-
tabase (Wiley), IndMED (ICMR-NIC), Ovid MEDLINE(R) (including In-Process & Other Non-Indexed 
Citations and Epub Ahead of Print), PakMediNet (PakCyber), PsycINFO (Ovid), and World Bank Group 
Research and Publications: Documents and Reports website.
The information specialist identified search terms and developed strategies through iterative testing of 
terms identified by the project team members and aided by known relevant papers. The search strategies 
were peer-reviewed by a second information specialist. MeSH and free text word synonyms were searched 
the concepts ‘common mental disorders’ (including depression and anxiety disorders), ‘non-communi-
cable diseases’ (cancer, diabetes, cardiovascular disease and COPD), ‘prevalence studies’ and ‘South Asia’. 
See Appendix 1 in Online Supplementary Document for full search strategies including resource cov-
erage dates where available.
We limited searches to studies published from 1990 onwards to ensure relevance to the current preva-
lence and determinants of CMDs.
We conducted this review within a short timeframe to inform research priorities at the start of the inter-
national IMPACT project. It was therefore not feasible to scan references of included studies, or to obtain 
unavailable papers.
Study selection
We included any observational studies that were published in any language, conducted in Bangladesh, 
India, or Pakistan, and assessed prevalence or determinants of CMD in adults with an NCD. Studies with 
the following criteria were included: observational studies including cross-sectional, case-control, and 
cohort studies, data collected in Bangladesh, India, or Pakistan, participants at least 18 years old, one of 
four key NCDs: cardiovascular disease (including stroke, hypertension, angina), diabetes (type II), cancer, 
and chronic respiratory disease, reporting on prevalence and/or determinants of one or multiple CMDs 
(depression and/or anxiety disorders), and identification of patients with CMD via clinical diagnosis, use 
of a recognised psychiatric diagnostic instrument (eg, SCID, CIDI), or through a validated screening tool 
(eg, PHQ-9, GAD-7, HADS).
We excluded studies meeting the following exclusion criteria: study designs other than observational, such 
as literature reviews, opinion papers, qualitative studies, posters and letters, studies with a sample size 
of less than 20 participants, data collected in multiple countries, without the possibility to extract coun-
try-specific information on Bangladesh, India, and/or Pakistan from the paper, studies with participants 
under 18 years of age, for which the review authors could not extract data for adults separately, studies 
reporting on the prevalence or determinants of CMD without reporting the use of a recognised diagnostic 
instrument or screening tool, and full-text papers not available within the review period.
Screening strategy
We stored and screened references in Mendeley reference management software (Elsevier, Amsterdam, 
the Netherlands, v 1.18). After removing duplicates, three researchers (EU, LN, IW) together screened 
titles and abstracts independently in duplicate, and disagreements were resolved through discussion, 
where required involving a third researcher. Two researchers independently screened all full-text papers 
(between EU, LN, and IW).
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Data extraction
After piloting the data extraction form, reviewers (EU, LN) extracted the following data in Microsoft Ex-
cel 2016 (Microsoft Inc, Seattle WA, USA): first author, year published, study objective, study population 
country (+region/ city), type of study, data source, participants, setting, sample size, CMD, CMD diag-
nostic criteria, NCD, NCD diagnostic criteria, type of prevalence estimate, key determinants, summary 
estimates of anxiety and depression prevalence, and comments.
Quality assessment
Two reviewers (LN, PM) independently used the appraisal tool for cross-sectional studies (AXIS) to assess 
the quality of studies included in the review [17]. This tool was chosen because we anticipated to identi-
fy mainly cross-sectional studies. A third reviewer (EU) assessed 10% of the studies for quality assurance 
and was available to discuss disagreements.
We computed a summary score weighing all 20 items equally for use in the meta-regression analysis, with 
a higher score indicating better quality.
Statistical analysis
Despite anticipated heterogeneity in the results of included studies, we judged that a meta-analysis that 
explores explanatory factors of heterogeneity is more useful than a systematic review without a quantita-
tive synthesis of results. Ioannidis and colleagues have previously discussed these considerations in de-
tail [18]. They argued that, providing limitations of synthesising heterogeneous results are adequately ac-
knowledged, quantitative syntheses can provide more information than qualitative interpretation of the 
results, and allow for an investigation of diversity in results.
One reviewer (EU) performed random-effects meta-analyses in Stata 15 (StataCorp, College Station TX, 
USA) under supervision of a statistician (NM), using the metaprop command for meta-analysis of pro-
portional data. We created forest plots to calculate pooled estimates where appropriate, by type of NCD.
To estimate heterogeneity, we calculated the I2 statistic. High heterogeneity is indicated if the I2 statistic is 
over 75% and low heterogeneity indicated if the I2 statistic is below 40% [19]. As we anticipated consid-
erable heterogeneity in the prevalence estimates of depression and anxiety, we employed random-effects 
meta-regression analyses with the metareg com-
mand in Stata 15 to explore factors associated 
with variations in prevalence estimates of CMD. 
Depending on the availability of data, covariates 
included year of publication (continuous vari-
able), setting (hospital vs other), country, CMD 
diagnostic tool (clinical assessment vs self- or 
interviewer-completed), and study quality (to-
tal score AXIS tool).
We investigated publication bias using fun-
nel plots. Where the number of studies al-
lowed for it, we performed sensitivity analyses 
of high-quality studies based on AXIS scores. 
For this purpose, we categorised studies with a 
quality score of 15 or higher (out of 20) as high 
overall quality.
RESULTS
Study characteristics
Out of 1654 non-duplicate records identified, 
96 were included in the review and 83 were in-
cluded for meta-analyses (Figure 1). Appendix 
S2 in Online Supplementary Document con-
tains a full reference list of all included studies.
Figure 1. Study selection process. CMD – common mental disorders, NCD 
– non-communicable disease.
Common mental disorders in Bangladesh, India and Pakistan
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Table 1 describes characteristics of the includ-
ed studies. Almost all studies were conducted in 
a hospital setting (94%). Studies were predom-
inantly conducted in India (63%), and most 
studies included patients with diabetes (42%), 
cardiovascular disease (28%), or cancer (24%). 
Depression was studied more commonly than 
anxiety (in 99% and 35% of studies, respective-
ly), and the HADS and PHQ-9 screening tools 
were most often used to screen for depression. 
Thirteen studies could not be included in the me-
ta-analyses, most commonly because the authors 
provided only a combined estimate for depres-
sion and anxiety rather than separate estimates.
We had initially planned to summarise evidence 
not only for the prevalence but also the determi-
nants of CMDs in adults with NCDs, but the lit-
erature identified was too inconsistent to provide 
a comprehensive overview.
Quality assessment
The results of the quality assessment, including 
all 96 studies, are shown in summary in Figure 
2, and in full in Figure S1 in Online Supple-
mentary Document. The most commonly iden-
tified quality issues were the sample frame and 
selection process, the description of the methods 
and basic data, and the description of non-re-
sponders.
The stated aims and objectives for many stud-
ies referred to plans to establish the prevalence 
of depression and/or anxiety in the population, 
with the population either undefined or defined 
in terms of geographical setting (mostly a coun-
try or region). However, the sample strategies 
described were often not adequate for achieving 
this goal. Although almost all studies were hos-
pital-based, study aims often implied the preva-
lence rates found in the studies would be relevant to the wider community. The potential and plausible 
differences in mental health between people attending a hospital for treatment of an NCD and those not 
seen in hospital were rarely considered.
Table 1. Description of study characteristics
Study characteriStic No. StudieS (N = 96)
Countries:
India 60
Pakistan 30
Bangladesh 5
All three countries 1
Study design:
Cross-sectional 86
Repeated measures (incl. before and after) 10
Sample size (of NCD patients):
20-49 9
50-200 56
>200 31
Recruitment setting:
Community 6
Hospital* 90
Common mental disorder (CMD):
Depression 62
Anxiety 1
Both depression and anxiety 33
CMD screening tool:
Patient Health Questionnaire (PHQ-9) 20
Hospital Anxiety and Depression Scale (HADS) 14
Diagnostic and Statistical Manual of Mental Disorders (DSM) 9
Beck’s Depression Inventory (BDI) 8
Hamilton Depression/Anxiety Rating Scale (HAM) 7
Montgomery-Åsberg Depression Rating Scale (MADRS) 4
Aga Khan University Anxiety and Depression Scale (AKU-ADS) 3
Geriatric Depression Scale (GDS) 3
Siddiqui-Shah Depression Scale (SSDS) 3
Other† 10
Multiple tools 15
Non-communicable disease:
Diabetes 40
Cardiovascular disease 27
Cancer 23
Respiratory conditions 4
Multiple conditions 2
*Includes patients recruited by phone or visit based on hospital records.
†Other tools: International Classification of Diseases- 10 (2), Center for Epidemiological 
Studies Depression Scale (2), Major Depression Inventory (1), Mini-International Neu-
ropsychiatric Interview (1), Depression Anxiety Stress Scales (1), Hopkins Symptoms 
Checklist-25 (1), Brief Edinburgh Depression Scale (1), and Mini-Mental State Exam-
ination (1).
Figure 2. Summary of quality assessment. Green: high quality. Orange: unclear 
quality. Red: low quality.
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In addition, people with previously diagnosed anxiety or depression, or those receiving antidepressants, 
were excluded from many studies that aimed to assess the prevalence of anxiety or depression in NCD 
populations.
Most studies did not mention how many people were missing from the source population due to non-re-
sponse, and almost none of the studies provided characteristics of these people. Very few authors reported 
they had calculated the required sample size ahead of conducting the study. Reporting of potential con-
flicts of interest and confirmation of obtained ethical consent were absent or unclear in 27% of the studies.
Meta-analysis
Eighty-three studies were included in the meta-analyses, providing 94 estimates of depression or anxiety. 
Some studies provided multiple estimates because they were conducted in various countries, because 
they reported on depression as well as anxiety, or because they included various NCD patient groups. Of 
the estimates for depression, six were from Bangladesh, 24 were from Pakistan and 64 from India. Of the 
estimates for anxiety, there were no estimates from Bangladesh, five from Pakistan, and 23 from India.
The pooled prevalence of depression from 94 estimates is 41% (95% CI = 37 to 44, I2 = 97%). Twen-
ty-eight studies provided data on the prevalence of anxiety, with a pooled estimate of 29% (95% CI = 22 
to 36, I2 = 96%).
Patients with diabetes
The pooled prevalence of depression from 43 estimates in 41 studies of patients with diabetes is 40% 
(95% CI = 34 to 45) (Figure 3).
Figure 3. Meta-analysis of the prevalence of depression in patients with diabetes. CMD – common mental disor-
ders, NCD – non-communicable disease. *Three estimates are included for Lloyd et al 2018 for data from Bangla-
desh, India, and Pakistan.
Common mental disorders in Bangladesh, India and Pakistan
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Heterogeneity was extremely high (I2 = 97%), with prevalence rates ranging between 2% and 84%. For 
the smaller group of studies not from India, estimates ranged between 16% and 62% for patients with 
diabetes and depression in Bangladesh, and between 15% and 74% in Pakistan.
The pooled prevalence of anxiety in eight studies of patients with diabetes is 29% (95% CI = 16 to 44, 
I2 = 97%). All but two estimates were from India; two studies from Pakistan reported estimates of 12% 
and 58% for anxiety in patients with diabetes [20,21].
Patients with cancer or cancer survivors
Nineteen studies reported prevalence rates of patients with cancer or cancer survivors. Many studies in-
cluded patients seen at inpatient or outpatient units with all types of cancer, while three studies focussed 
on a specific type of cancer: head and neck cancer, prostate- and breast cancer [22-24]. The pooled prev-
alence of depression in these studies of patients with cancer was 37% (95% CI = 30 to 45, I2 = 94%) (Fig-
ure 4). All but four estimates were from India; four studies from Pakistan reported depression prevalence 
rates between 10% and 65% for people with cancer.
Eleven of the studies that reported on prevalence of depression also reported on the prevalence of anxiety. 
Pooling the studies resulted in a combined estimate of 27% (95% CI = 16 to 40, I2 = 97%). Two studies 
were from Pakistan rather than India; these reported prevalence rates of 33% and 23% [25,26].
Patients with cardiovascular disease
The 24 studies of CMD in patients with cardiovascular disease included studies of patients with angi-
na (n = 1), unspecified cardiovascular or cardiac disease (n = 5), heart failure (n = 2), hypertension (n = 4), 
stroke (n = 6), coronary artery disease (n = 5), and myocardial infarction (n = 1). We performed meta-anal-
yses for hypertension and stroke, as these were considered the two most homogenous chronic illness 
groups. Both groups consisted of patients with the same diagnosis, contrary to the other groups compris-
ing more than one study, in which the type of diagnosis and assessment varied The pooled prevalence of 
depression in patients with hypertension was 38% (95% CI = 32 to 45, I2 = 91%) and the pooled preva-
lence of depression in patients with a previous stroke was 39% (95% CI = 23 to 56, I2 = 96%).
The reported prevalence of anxiety, which was estimated in patients with stroke, coronary artery disease, 
myocardial infarction, and unspecified heart disease, ranged from 3% to 58%.
Figure 4. Meta-analysis of the prevalence of depression in patients with cancer CMD – common mental disorders, 
NCD – non-communicable disease.
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Patients with chronic respiratory conditions
Seven studies, six from India and one from Pakistan, reported on the prevalence of CMD in patients with 
chronic respiratory conditions. One of these studies measured a prevalence of depression of 30% in pa-
tients with bronchial asthma [27], one reported 19% anxiety among 59 patients with COPD [28], and 
six reported on the prevalence of depression in patients with COPD (Figure 5) (pooled estimate 44%, 
95% CI = 26 to 62, I2 95%). The study of depression in patients with COPD from Pakistan reported a 
prevalence of 15% [29].
Figure 5. Meta-analysis of the prevalence of depression in patients with COPD CMD – common mental disorders, 
NCD – non-communicable disease, COPD – chronic obstructive pulmonary disease.
Risk of publication bias
To assess the risk of bias we constructed and visually inspected a funnel plot of prevalence estimates of 
depression, to which all but one of the studies contributed data (Figure S2 in Online Supplementary 
Document). Visual inspection of the funnel plot shows a flat funnel-shaped distribution due to the large 
amount of relatively small studies, the lack of medium-sized samples, and a few very large studies. The 
studies with large sample sizes tend to have a lower prevalence rate of depression.
Sensitivity analysis of high-quality studies
Including 29 high quality studies only (quality score ≥15 out of 20), the pooled prevalence of depression 
for all NCD categories is 35% (95% CI = 0.30 to 0.41, I2 = 98%). Only three studies reporting on the prev-
alence of anxiety in diabetes, cancer, and stroke, respectively, were rated high quality, producing a pooled 
estimate of 33% (95% CI = 0.10 to 0.62, I2 = 99%).
Meta-regression
Restricted by the availability of reliable data on patient and study characteristics, we included the follow-
ing variables in the meta-regression analysis for depression prevalence: year of publication, country, NCD 
category, sample size (categorical), type of CMD diagnostic tool (diagnostic interview vs screening tool), 
and the total score of study quality.
The apparent associations between a higher prevalence of depression and a more recent publication date 
and lower quality score had limited impact on explaining heterogeneity (adjusted r2 = 0.4%). None of the 
covariates were statistically significant (Table S1 in Online Supplementary Document).
For the meta-regression analysis modelling anxiety prevalence, year of publication, sample size, and qual-
ity score were included. For all other variables, some categories had cell counts of less than five and were 
Common mental disorders in Bangladesh, India and Pakistan
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therefore not included. These covariates explained more of the heterogeneity for anxiety prevalence (ad-
justed r2 = 11%) than for depression. However, again none of the covariates were statistically significant 
predictors of prevalence estimates (Table S2 in Online Supplementary Document).
DISCUSSION
Summary of findings
Ninety-six studies reported on the prevalence of CMDs in patients with NCDs in Bangladesh, India, or 
Pakistan, in predominantly hospital-based studies. The pooled estimate of depression was 40% in pa-
tients with diabetes, 37% in patients with cancer, 38% in patients with hypertension, 39% in patients 
with stroke, and 44% in patients with COPD. The pooled prevalence of anxiety was 29% in patients with 
diabetes and 27% in patients with cancer.
For all four NCDs, findings were extremely heterogeneous, for example, the prevalence of depression in 
patients with diabetes ranged from 2% to 84%. The meta-regression analyses did not reveal study char-
acteristics associated with the reported prevalence estimates of depression and anxiety. Study country was 
also not associated with prevalence of either depression or anxiety. However, a sensitivity analysis with 
high quality studies only estimated a pooled prevalence of depression across NCDs of 35%, lower than 
the 41% found in the main analysis.
Limitations
For studies of prevalence, which summarise data from observational studies of patients with varying char-
acteristics and from a wide range of settings, heterogeneity in the estimates is to be expected. However, 
despite our efforts to conduct a high-quality systematic review, it is likely that the quality and heteroge-
neity of the included studies affect the reliability of the findings.
Limitations of the primary evidence included a mismatch between intended study population and sampling 
strategies, no mention of participants who did not complete questionnaires or people who were approached 
but did not join the study, and limited descriptions of study methods and participant characteristics.
Most studies excluded patients who had a diagnosis of depression or anxiety, or who were already receiv-
ing medication to treat a CMD prior to inclusion in the study. Estimates for these studies therefore reflect 
undiagnosed depression or anxiety, rather than the point prevalence estimate of common mental disor-
der in the total population of patients with NCDs. Prevalence rates we reported are therefore likely to be 
underestimates of the true prevalence.
Although we explored variation in estimates related to whether a diagnostic interview or screening tool 
was used to identify depression and/ or anxiety, the type of screening tool, translation and validation of 
the tool, and how and by whom screening was performed, may explain some of the heterogeneity iden-
tified. Many different screening tools were identified (Table 1). The most commonly used tools, such as 
the PHQ-9, HADS, MADRS, BDI, and HAM have been widely translated and validated. However, not 
all studies reported whether an appropriately translated version was used. Some studies used less estab-
lished measures without reporting on validation or translation of the tool, and some studies used multiple 
tools. Authors generally conducted studies in large, metropolitan hospitals with the resources to conduct 
research. Only 6 were community studies. This limits the generalisability of our findings, as the group 
of patients with NCDs attending these settings are likely to differ from those who attend smaller, region-
al hospitals or those who do not regularly visit the hospital due to either limited access to health care or 
a lower severity of illness. However, prevalence rates were still found to be high in community studies 
included in our review. Depression in patients with diabetes for example was found to be between 15% 
and 36%. A review of studies on diabetes and depression internationally reported a prevalence of 20% in 
12 community studies, compared to 32% in studies with a clinic setting [30].
It is possible that we missed relevant studies, particularly those published in journals specific to South-
Asia. Although we searched in databases from Bangladesh, India, and Pakistan, these databases are more 
difficult to search due to their limited search interface. Our decision not to include grey literature is also 
likely to have reduced the number of studies we identified.
Methodology for systematic reviews and meta-analyses of prevalence studies is underdeveloped compared 
to methods and guidance for evidence synthesis of randomised controlled trials and treatment studies. 
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To our knowledge, no widely accepted and validated tool for quality assessment of prevalence studies 
is available. Although we used a quality assessment tool developed for use with cross-sectional studies, 
[17] we found that the nature of the included studies meant assessment was subjective and extremely 
time-consuming. We see room for improvement of the tool, by providing more explicit guidance to the 
different items (for example, when are ‘basic data adequately described’?), and by re-assessing the weight 
given to certain indicators of study quality (for example, three out of 20 items address response rate and 
non-responder bias). We used summary scores of study quality weighing all items equally, as the tool de-
velopers provided no guidance for calculating summary scores.
Some studies provided multiple estimates, either for multiple NCDs or for anxiety as well as depression. By 
including these estimates in one meta-regression analysis, we will have underestimated the between-study 
variation. Similarly, the pooled estimate for depression in diabetes includes three estimates from the same 
study in three different countries. As it is highly unlikely that this would have a substantial impact on the 
results, we have not adjusted for this.
Implications for research and practice
Given the heterogeneity of our findings and the quality issues identified in many of the included studies, 
the pooled estimates should not be interpreted as true estimates of the average prevalence rate of CMDs 
in people with NCDs in these three South Asian countries. Most of the estimates provided reflect the bur-
den of disease in a hospital population with no previous diagnosis or treatment of mental ill health. The 
meta-regression analyses explained little of the variance in prevalence rates identified. Our findings also 
do not explain how prevalence rates of CMDs vary between patient groups. For example, most studies 
we included had a mixed sample of men and women and estimates of depression and anxiety are likely 
to differ by gender.
Our systematic review shows that gaps remain in knowledge on the burden of disease for CMDs and 
NCDs in Bangladesh, India, and Pakistan. Large and well-conducted community surveys, representative 
of the entire population of patients with NCDs, would make a valuable contribution to research on the 
burden of physical and mental comorbidities in South Asia, and provide robust data to policymakers to 
map demand for services. Worldwide case-control studies which have aimed to investigate associations 
between psychosocial factors and heart disease include the INTERHEART and INTERSTROKE studies 
[31,32]. For South Asia, the INTERHEART study reported a 30% prevalence rate of depression for those 
who suffered from a myocardial infarction, compared to 19% depression in the control group, around 
the year 2000 [30]. In the INTERSTROKE study, patients from South Asia with acute stroke were found 
to be at higher odds of psychosocial stress, including depression, than a control group [32].
CMDs and NCDs have a large impact on people’s quality of life and living with anxiety or depression on 
top of a long-term physical illness can lead to greater physical deterioration, functional impairment, low-
er adherence to medication, and premature mortality [33,34]. However, successful implementation of 
integrated care for people with NCDs, including CMDs, faces many barriers. A recent review pointed to-
wards a lack of commitment from actors at all levels, which translates into limited human resources and 
skills, insufficient coordination of policies, and low workforce preparedness [35]. If mental and physical 
comorbidity is as common as suggested by our findings, practitioners and policymakers must act at the 
clinical and the policy level, to make high quality and tailored mental health care available to patients 
with NCDs. This is particularly relevant in low- and middle-income countries, where current resources 
and infrastructure may not be able to accommodate such comprehensive mental health care.
CONCLUSIONS
Although the wide variation in estimates of CMDs limits our ability to draw definite conclusions on prev-
alence rates of CMDs in these patient groups, it is clear that the prevalence of depression and anxiety is 
high in people with NCDs in South Asia. Prevalence rates between 20 and 30% are among the lower-end 
estimates and constitute a great burden of mental ill health for which there is currently little attention in 
either research, practice, or policy.
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